Current and former Tesla employees working in the company's open-air "tent" factory say they felt pressure to take shortcuts to hit aggressive Model 3 production goals,...Technologyread more
President Donald Trump and the RNC are picking up key supporters in the business community who did not back him as a candidate in 2016.2020 Electionsread more
Early Facebook investor and Trump supporter Peter Thiel weighed in on the Democrats taking on the president in 2020, saying he was "most scared' by Elizabeth Warren.Politicsread more
Tensions between Japan and South Korea come as the U.S. and its trading partners are embroiled in a global trade war.Technologyread more
The one-to-eight stock split would mean the current number of ordinary shares — which stands at 4 billion — will increase to 32 billion. It comes ahead of a reported Hong Kong...Asia Marketsread more
Treasury Secretary Steven Mnuchin is raising red flags ahead of Facebook's proposed cryptocurrency launch.Marketsread more
China's fiscal spending increased 10.7% in the first six months from a year earlier, the finance ministry said on Tuesday, underlining the government's bid to support the...China Economyread more
Beto O'Rourke's campaign for the 2020 election raised just $3.6 million in the second quarter of this year, putting him in the lower tier of candidates who have struggled to...2020 Electionsread more
Von der Leyen, one of the longest serving ministers in Germany, has tried to woo European lawmakers over the last two weeks.Europe Newsread more
The findings by McKinsey and Company come amid a year-long tariff fight between the U.S. and China, which has spilled into areas such as technology and security.China Economyread more
Microsoft's considerable reach into the corporate world isn't something Slack CEO Stewart Butterfield is very concerned about.Technologyread more
Check out the companies making headlines midday Monday:
Boeing — Shares of Boeing dropped 4.44% after Bank of America Merrill Lynch cut its rating to neutral from buy after Boeing announced it plans to cut production of the jet on Friday. The bank expects delays with 737 will last six to nine months.
Southwest Airlines — The airline fell 2.46% after Raymond James downgraded it to hold from buy, citing concerns that Boeing jet groundings could last through peak summer travel. Southwest has 34 Max jets which account for roughly 4 percent of the airline's passenger capacity.
General Electric — GE tumbled 5.19% after J.P. Morgan's Stephen Tusa downgraded the stock underweight from neutral and cut his 12-month price target to $5 from $6. "We believe many investors are underestimating the severity of the challenges and underlying risks at GE, while overestimating the value of small positives," wrote Tusa in a note to clients.
Sony — Shares of Sony surged 7.3% and ended the day little changed after Reuters reported that Daniel Loeb's Third Point is building a stake in the company and plans to push for changes. Third Point is reportedly raising an investment vehicle to generate between $500 million and $1 billion to continue buying Sony shares. This is the second time in 6 years that the hedge fund has targeted Sony.
J. Alexander Holdings — The Southern restaurant chain's stock rallied more than 8% after activist investor Ancora Advisors announced an offer to take the company private for $11.75 per share. The offering represented more than a 12% premium to Friday's closing price.
Symantec — Symantec jumped more than 5% after an analyst at Goldman Sachs upgraded the stock to buy from neutral, highlighting an "undemanding" valuation and a "to sustained growth in current billings."
AMC Entertainment — Shares of the movie theater company surged 92u% after B. Riley FBR upgraded them to buy from neutral. The firm cited a strong line-up of films coming out in the spring and summer, which includes Marvel's "Avengers: Endgame."
2U — Shares of the educational technology company dropped about 3.4% after 2U announced it is purchasing Trilogy Education Services for $750 million.
United Therapeutics —United Therapeutics fell around 5.7% after the company announced its clinical study of esuberaprost tablets did not meet its primary endpoint. The biotechnology company is discontinuing product development for the pulmonary arterial hypertension treatment.